FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012667850> ?p ?o ?g. }

• W2012667850 endingPage "330" @default.
• W2012667850 startingPage "320" @default.
• W2012667850 abstract "An ethylene-vinyl acetate (EVA) matrix containing glimepiride was prepared as a potential transdermal drug delivery system. Permeation studies of quinupramine through the EVA copolymer membrane were carried out using a two-chamber diffusion cell. The rate of drug permeation through the EVA membrane was proportional to the PEG 400 volume fraction. The release of glimepiride from the EVA matrix was examined using a modified Franz diffusion cell. A plasticizer was added to prepare the pore structure of the EVA matrix in order to increase the rate of drug release. The effects of PEG 400, drug concentration, temperature, and plasticizer on the drug release rate were investigated. Various types of enhancers were added to an EVA matrix containing 2% glimepiride in an attempt to increase the level of skin permeation of quinupramine through an EVA matrix. The effects of the enhancers on the level of glimepiride permeation through the skin were evaluated using Franz diffusion cells fitted with intact excised rat skin. The rate of drug release from the EVA matrix increased with increasing PEG 400 volume fraction, temperature, and drug loading. The estimated activation energy of drug release was 7.274 kcal/mol for 2% drug loading dose. The release of glimepiride from the EVA matrix followed a diffusion-controlled model, where the quantity released per unit area was proportional to the square root of time. The controlled release of glimepiride was achieved using the EVA polymer including the plasticizer. Among the plasticizers used, such as the alkyl citrates and phthalates groups, diethyl phthalate slightly increased the rate of glimepiride release. Among the various enhancers used, such as the non-ionic surfactants, the glycerides, the propylene glycol derivatives, fatty acids (saturated or unsaturated), and pyrrolidones, linoleic acid showed the highest permeation rate; 3.17-times higher than the control. In conclusion, an EVA matrix containing a permeation enhancer can be used for the transdermal controlled delivery of glimepiride." @default.
• W2012667850 created "2016-06-24" @default.
• W2012667850 creator A5004316569 @default.
• W2012667850 creator A5011692309 @default.
• W2012667850 creator A5017561837 @default.
• W2012667850 creator A5023569205 @default.
• W2012667850 date "2009-07-17" @default.
• W2012667850 modified "2023-09-26" @default.
• W2012667850 title "Enhanced transdermal controlled delivery of glimepiride from the ethylene-vinyl acetate matrix" @default.
• W2012667850 cites W1495654615 @default.
• W2012667850 cites W1546249647 @default.
• W2012667850 cites W1964921665 @default.
• W2012667850 cites W1967020885 @default.
• W2012667850 cites W1977624927 @default.
• W2012667850 cites W1983473009 @default.
• W2012667850 cites W1988322330 @default.
• W2012667850 cites W1993144465 @default.
• W2012667850 cites W1994417792 @default.
• W2012667850 cites W1997847826 @default.
• W2012667850 cites W2000243162 @default.
• W2012667850 cites W2003315673 @default.
• W2012667850 cites W2003371745 @default.
• W2012667850 cites W2003864627 @default.
• W2012667850 cites W2008258601 @default.
• W2012667850 cites W2008458490 @default.
• W2012667850 cites W2008651021 @default.
• W2012667850 cites W2013276765 @default.
• W2012667850 cites W2014770831 @default.
• W2012667850 cites W2018038125 @default.
• W2012667850 cites W2020203593 @default.
• W2012667850 cites W2021676731 @default.
• W2012667850 cites W2026582123 @default.
• W2012667850 cites W2034475816 @default.
• W2012667850 cites W2035632119 @default.
• W2012667850 cites W203718706 @default.
• W2012667850 cites W2038916844 @default.
• W2012667850 cites W2041250042 @default.
• W2012667850 cites W2042660711 @default.
• W2012667850 cites W2056411340 @default.
• W2012667850 cites W2059554244 @default.
• W2012667850 cites W2061089283 @default.
• W2012667850 cites W2062704583 @default.
• W2012667850 cites W2066990963 @default.
• W2012667850 cites W2068059445 @default.
• W2012667850 cites W2069348831 @default.
• W2012667850 cites W2072262758 @default.
• W2012667850 cites W2072614860 @default.
• W2012667850 cites W2074832039 @default.
• W2012667850 cites W2079859568 @default.
• W2012667850 cites W2086130473 @default.
• W2012667850 cites W2117601516 @default.
• W2012667850 cites W2128404895 @default.
• W2012667850 cites W2169224003 @default.
• W2012667850 cites W2319351546 @default.
• W2012667850 cites W2319725172 @default.
• W2012667850 cites W2481049584 @default.
• W2012667850 cites W3127648950 @default.
• W2012667850 cites W4240821889 @default.
• W2012667850 cites W4255395780 @default.
• W2012667850 doi "https://doi.org/10.1080/10717540903031084" @default.
• W2012667850 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19606946" @default.
• W2012667850 hasPublicationYear "2009" @default.
• W2012667850 type Work @default.
• W2012667850 sameAs 2012667850 @default.
• W2012667850 citedByCount "11" @default.
• W2012667850 countsByYear W20126678502014 @default.
• W2012667850 countsByYear W20126678502016 @default.
• W2012667850 countsByYear W20126678502017 @default.
• W2012667850 countsByYear W20126678502019 @default.
• W2012667850 countsByYear W20126678502021 @default.
• W2012667850 countsByYear W20126678502022 @default.
• W2012667850 crossrefType "journal-article" @default.
• W2012667850 hasAuthorship W2012667850A5004316569 @default.
• W2012667850 hasAuthorship W2012667850A5011692309 @default.
• W2012667850 hasAuthorship W2012667850A5017561837 @default.
• W2012667850 hasAuthorship W2012667850A5023569205 @default.
• W2012667850 hasConcept C134018914 @default.
• W2012667850 hasConcept C15920480 @default.
• W2012667850 hasConcept C159985019 @default.
• W2012667850 hasConcept C185592680 @default.
• W2012667850 hasConcept C192562407 @default.
• W2012667850 hasConcept C205679159 @default.
• W2012667850 hasConcept C2776307423 @default.
• W2012667850 hasConcept C2776481364 @default.
• W2012667850 hasConcept C2777180221 @default.
• W2012667850 hasConcept C2780762185 @default.
• W2012667850 hasConcept C2781005124 @default.
• W2012667850 hasConcept C41625074 @default.
• W2012667850 hasConcept C43617362 @default.
• W2012667850 hasConcept C50670333 @default.
• W2012667850 hasConcept C521977710 @default.
• W2012667850 hasConcept C55493867 @default.
• W2012667850 hasConcept C555293320 @default.
• W2012667850 hasConcept C58968531 @default.
• W2012667850 hasConcept C71924100 @default.
• W2012667850 hasConcept C98274493 @default.
• W2012667850 hasConceptScore W2012667850C134018914 @default.
• W2012667850 hasConceptScore W2012667850C15920480 @default.

• next